Key result
Anticoagulation improved presumed valve thrombosis in three cases of valve-in-valve restenosis following transcatheter aortic valve replacement.
Why the study?
Does anticoagulation improve thrombotic aortic valve restenosis after valve-in-valve TAVR?
Case Report (n=3)
Does anticoagulation improve thrombotic aortic valve restenosis after valve-in-valve TAVR?
Anticoagulation may be an effective treatment for reversible thrombotic aortic valve restenosis following valve-in-valve TAVR.
May support anticoagulation for suspected thrombotic restenosis after valve-in-valve TAVR; hypothesis-generating and requires prospective validation.
Thrombotic aortic valve restenosis following transcatheter aortic valve replacement (TAVR) has not been extensively reported and the rates of TAVR valve thrombosis are not known. We present three cases of valve-in-valve (VIV) restenosis following TAVR with the balloon expandable transcatheter heart valves, presumably due to valve thrombosis that improved with anticoagulation.
No takes yet. Share an insight, caveat, or question.
Goleski et al. (2016) conducted a case report in Valve-in-valve (VIV) restenosis following TAVR (n=3). Anticoagulation was evaluated on Improvement of valve thrombosis. Anticoagulation improved presumed valve thrombosis in three cases of valve-in-valve restenosis following transcatheter aortic valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: